
FDA Inspects Granules Hyderabad Plant, Issues 11 Observations
The story in brief
The U.S. FDA inspected Granules India’s finished dosage facility in Gagillapur, Hyderabad, from October 19-30, 2026, as part of a CGMP check. The inspection resulted in 11 observations issued in a Form FDA 483, unrelated to data integrity or cross-contamination. The company stated there is no impact on manufacturing or distribution of products from the site. Granules India plans to submit a comprehensive response to the FDA within 15 business days.